Drugs / CyPep-1
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05383170 | Mar 2023 → Sep 2024 | breast cancer, head and neck squamous cell carcinoma, melanoma | Cytovation AS | Completed | No outcome recorded |
| Phase 1/2 | NCT04260529 | Apr 2020 → Jul 2024 | cancer of unknown primary site | Cytovation AS | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03846648 Comparator | Mar → Dec 2019 | common wart | Centre for Human Drug Research, Netherlands | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CyPep-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05383170 ↗ |
| Modality | Peptide | “CyPep-1 is a chemically synthesized peptide with oncolytic properties.” NCT04260529 ↗ |
| Route | Topical | “topically applied CyPep-1” NCT03846648 ↗ |